Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1088)	8/14/1998 11:54:00 AM
From: gy	Respond to of 1826

Is this our very own Richard Dean Bagnell? Yes, I think so. He is a chemist working in UCSD. His name on the paper must be due to that he was involved in sythsizing the compound. Authors : Kelner MJ. Mcmorris TC. Estes L. Samson KM. Bagnell RD. Taetle R. Title : EFFICACY OF MGI 114 (6-HYDROXYMETHYLACYLFULVENE, HIMAF) AGAINST THE MDR1/GP170 METASTATIC MV522 LUNG CARCINOMA XENOGRAFT Source: \| European Journal of Cancer. 34(6):908-913, 1998 May. \| + Abstract \| Illudins are a novel class of agents with a chemical structure entirely different from current chemotherapeutic agents. A new semisynthetic derivative, MGI 114 (NSC68386-hydroxymethyl-acylfulvene, HMAF), is markedly effective in a variety of lung, breast and colon carcinoma xenograft models. This analogue, MGI 114, is currently in phase I human clinical trials, and is scheduled for two different phase II trials. To determine if MGI 114 could be effective in vivo against mdr tumour cells, we generated an mdr1/gp170-positive clone of the metastatic MV522 human lung carcinoma line by transfecting a eukaryotic expression vector containing the cDNA encoding for the human gp170 protein. This MV522/mdr1 daughter line retained the metastatic ability of parental cells. Closeparental MV522 xenograft is mildly responsive in vivo to mitomycin C and paciltaxel, as evidenced by partial tumour growth inhibition and a small increase in Life span, whereas MV522/mdr1 xenografts were resistant to these agents. In contrast to mitomycin C and paciltaxel, MGI 114 produced xenograft tumour regressions in 32 of 32 animals and completely eliminated tumours in more than 30% of MV522/mdr1 tumour-bearing mice. Thus, MGI 114 should be effective in vivo against mdr1/gp170-positive tumours. Institution. \| Reprint available from: * Kelner MJ \| UNIV CALIF SAN DIEGO \| MED CTR \| DEPT PATHOL \| MAIL CODE 8320